Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel and Cisplatin in Advanced NSCLC
NCT00118131Phase 2Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Dec 2003
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Overall Tumor Response Rate at 7 years. Started Dec 2003; status: terminated.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00118131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118131.